FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 330:484-489 February 17, 1994 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Multiple myeloma accounts for 10 percent of hematologic cancers and kills approximately 10,000 Americans each year. The disease is more common in older persons, and blacks are affected twice as frequently as whites. The cause of multiple myeloma is unknown, and its extent, complications, sensitivity to drugs, and clinical course vary widely among patients. Since many aspects of the biology of this disease have recently been discussed elsewhere,¹ this review will focus on treatment.

Solitary Bone Myeloma

Approximately 3 percent of patients have only one bone lesion and no evidence of bone marrow plasmacytosis. Fifty percent of such patients have low concentrations of . . . [Full Text of this Article]

Asymptomatic Multiple Myeloma

Multiple Myeloma

Management of Common Complications

Primary Chemotherapy

Maintenance Treatment

Unresponsive or Relapsing Myeloma

VAD-Resistant Myeloma

Myeloablative Therapies

Conclusions

Source Information

From the University of Texas M.D. Anderson Cancer Center, Houston.

Address reprint requests to Dr. Alexanian at Box 1, 1515 Holcombe Blvd., Houston, TX 77030.

References

This article has been cited by other articles:

• Du, W., Hattori, Y., Yamada, T., Matsumoto, K., Nakamura, T., Sagawa, M., Otsuki, T., Niikura, T., Nukiwa, T., Ikeda, Y. (2007). NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor. Blood 109: 3042-3049 [Abstract] [Full Text]  
• Berenson, J. R., Matous, J., Swift, R. A., Mapes, R., Morrison, B., Yeh, H. S. (2007). A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma. Clin. Cancer Res. 13: 1762-1768 [Abstract] [Full Text]  
• Richardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., Munshi, N. C., Kelly-Colson, K., Doss, D., McKenney, M. L., Gorelik, S., Warren, D., Freeman, A., Rich, R., Wu, A., Olesnyckyj, M., Wride, K., Dalton, W. S., Zeldis, J., Knight, R., Weller, E., Anderson, K. C. (2006). A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108: 3458-3464 [Abstract] [Full Text]  
• Korbet, S. M., Schwartz, M. M. (2006). Multiple Myeloma. J. Am. Soc. Nephrol. 17: 2533-2545 [Full Text]  
• Duyvendak, M., Naunton, M., Kingma, B. J, Brouwers, J. R. (2005). Thalidomide-Associated Thrombocytopenia. The Annals of Pharmacotherapy 39: 1936-1939 [Abstract] [Full Text]  
• Bae, J., Martinson, J. A., Klingemann, H. G. (2005). Identification of CD19 and CD20 Peptides for Induction of Antigen-Specific CTLs against B-Cell Malignancies. Clin. Cancer Res. 11: 1629-1638 [Abstract] [Full Text]  
• Zeifang, F., Zahlten-Hinguranage, A., Goldschmidt, H., Cremer, F., Bernd, L., Sabo, D. (2005). Long-term survival after surgical intervention for bone disease in multiple myeloma. Ann Oncol 16: 222-227 [Abstract] [Full Text]  
• Bross, P. F., Kane, R., Farrell, A. T., Abraham, S., Benson, K., Brower, M. E., Bradley, S., Gobburu, J. V., Goheer, A., Lee, S.-L., Leighton, J., Liang, C. Y., Lostritto, R. T., McGuinn, W. D., Morse, D. E., Rahman, A., Rosario, L. A., Verbois, S. L., Williams, G., Wang, Y.-C., Pazdur, R. (2004). Approval Summary for Bortezomib for Injection in the Treatment of Multiple Myeloma. Clin. Cancer Res. 10: 3954-3964 [Full Text]  
• Barlogie, B., Shaughnessy, J., Tricot, G., Jacobson, J., Zangari, M., Anaissie, E., Walker, R., Crowley, J. (2004). Treatment of multiple myeloma. Blood 103: 20-32 [Abstract] [Full Text]  
• Maloney, D. G., Molina, A. J., Sahebi, F., Stockerl-Goldstein, K. E., Sandmaier, B. M., Bensinger, W., Storer, B., Hegenbart, U., Somlo, G., Chauncey, T., Bruno, B., Appelbaum, F. R., Blume, K. G., Forman, S. J., McSweeney, P., Storb, R. (2003). Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 102: 3447-3454 [Abstract] [Full Text]  
• Souliotis, V. L., Dimopoulos, M. A., Sfikakis, P. P. (2003). Gene-specific Formation and Repair of DNA Monoadducts and Interstrand Cross-links after Therapeutic Exposure to Nitrogen Mustards. Clin. Cancer Res. 9: 4465-4474 [Abstract] [Full Text]  
• Giralt, S., Bensinger, W., Goodman, M., Podoloff, D., Eary, J., Wendt, R., Alexanian, R., Weber, D., Maloney, D., Holmberg, L., Rajandran, J., Breitz, H., Ghalie, R., Champlin, R. (2003). 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials. Blood 102: 2684-2691 [Abstract] [Full Text]  
• Lee, C.-K., Barlogie, B., Munshi, N., Zangari, M., Fassas, A., Jacobson, J., van Rhee, F., Cottler-Fox, M., Muwalla, F., Tricot, G. (2003). DTPACE: An Effective, Novel Combination Chemotherapy With Thalidomide for Previously Treated Patients With Myeloma. JCO 21: 2732-2739 [Abstract] [Full Text]  
• Segeren, C. M., Sonneveld, P., van der Holt, B., Vellenga, E., Croockewit, A. J., Verhoef, G. E. G., Cornelissen, J. J., Schaafsma, M. R., van Oers, M. H. J., Wijermans, P. W., Fibbe, W. E., Wittebol, S., Schouten, H. C., Kooy, M. v. M., Biesma, D. H., Baars, J. W., Slater, R., Steijaert, M. M. C., Buijt, I., Lokhorst, H. M. (2003). Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 101: 2144-2151 [Abstract] [Full Text]  
• Nabhan, C., Gajria, D., Krett, N. L., Gandhi, V., Ghias, K., Rosen, S. T. (2002). Caspase Activation Is Required for Gemcitabine Activity in Multiple Myeloma Cell Lines. Molecular Cancer Therapeutics 1: 1221-1227 [Abstract] [Full Text]  
• Rajendran, J. G., Eary, J. F., Bensinger, W., Durack, L. D., Vernon, C., Fritzberg, A. (2002). High-Dose 166Ho-DOTMP in Myeloablative Treatment of Multiple Myeloma: Pharmacokinetics, Biodistribution, and Absorbed Dose Estimation. JNM 43: 1383-1390 [Abstract] [Full Text]  
• Ohno, S., Yoshimoto, M., Honda, S., Miyachi, S., Ishida, T., Itoh, F., Endo, T., Chiba, S., Imai, K. (2002). The Antisense Approach in Amyloid Light Chain Amyloidosis: Identification of Monoclonal Ig and Inhibition of Its Production by Antisense Oligonucleotides in In Vitro and In Vivo Models. J. Immunol. 169: 4039-4045 [Abstract] [Full Text]  
• Greenstein, S., Ghias, K., Krett, N. L., Rosen, S. T. (2002). Mechanisms of Glucocorticoid-mediated Apoptosis in Hematological Malignancies. Clin. Cancer Res. 8: 1681-1694 [Abstract] [Full Text]  
• Gartenhaus, R. B., Prachand, S. N., Paniaqua, M., Li, Y., Gordon, L. I. (2002). Arsenic Trioxide Cytotoxicity in Steroid and Chemotherapy-resistant Myeloma Cell Lines: Enhancement of Apoptosis by Manipulation of Cellular Redox State. Clin. Cancer Res. 8: 566-572 [Abstract] [Full Text]  
• Moehler, T. M., Neben, K., Benner, A., Egerer, G., Krasniqi, F., Ho, A. D., Goldschmidt, H. (2001). Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood 98: 3846-3848 [Abstract] [Full Text]  
• Attaelmannan, M., Levinson, S. S. (2000). Understanding and Identifying Monoclonal Gammopathies. Clin. Chem. 46: 1230-1238 [Abstract] [Full Text]  
• Pascual, F. E., Matthay, M. A., Bacchetti, P., Wachter, R. M. (2000). Assessment of Prognosis in Patients With Community-Acquired Pneumonia Who Require Mechanical Ventilation. Chest 117: 503-512 [Abstract] [Full Text]  
• Lenhoff, S., Hjorth, M., Holmberg, E., Turesson, I., Westin, J., Nielsen, J. L., Wisloff, F., Brinch, L., Carlson, K., Carlsson, M., Dahl, I.-M., Gimsing, P., Hippe, E., Johnsen, H., Lamvik, J., Lofvenberg, E., Nesthus, I., Rodjer, S. (2000). Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Blood 95: 7-11 [Abstract] [Full Text]  
• Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeldis, J., Barlogie, B., Siegel, D., Crowley, J. (1999). Antitumor Activity of Thalidomide in Refractory Multiple Myeloma. NEJM 341: 1565-1571 [Abstract] [Full Text]  
• Palumbo, A., Triolo, S., Argentino, C., Bringhen, S., Dominietto, A., Rus, C., Omede, P., Tarella, C., Pileri, A., Boccadoro, M. (1999). Dose-Intensive Melphalan With Stem Cell Support (MEL100) Is Superior to Standard Treatment in Elderly Myeloma Patients. Blood 94: 1248-1253 [Abstract] [Full Text]  
• Massaia, M., Borrione, P., Battaglio, S., Mariani, S., Beggiato, E., Napoli, P., Voena, C., Bianchi, A., Coscia, M., Besostri, B., Peola, S., Stiefel, T., Even, J., Novero, D., Boccadoro, M., Pileri, A. (1999). Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy. Blood 94: 673-683 [Abstract] [Full Text]  
• Ozaki, S., Kosaka, M., Wakahara, Y., Ozaki, Y., Tsuchiya, M., Koishihara, Y., Goto, T., Matsumoto, T. (1999). Humanized Anti-HM1.24 Antibody Mediates Myeloma Cell Cytotoxicity That Is Enhanced by Cytokine Stimulation of Effector Cells. Blood 93: 3922-3930 [Abstract] [Full Text]  
• Rajkumar, S. V., Fonseca, R., Lacy, M. Q., Witzig, T. E., Therneau, T. M., Kyle, R. A., Litzow, M. R., Gertz, M. A., Greipp, P. R. (1999). Plasmablastic Morphology Is an Independent Predictor of Poor Survival After Autologous Stem-Cell Transplantation for Multiple Myeloma. JCO 17: 1551-1551 [Abstract] [Full Text]  
• Vescio, R., Schiller, G., Stewart, A. K., Ballester, O., Noga, S., Rugo, H., Freytes, C., Stadtmauer, E., Tarantolo, S., Sahebi, F., Stiff, P., Meharchard, J., Schlossman, R., Brown, R., Tully, H., Benyunes, M., Jacobs, C., Berenson, R., DiPersio, J., Anderson, K., Berenson, J. (1999). Multicenter Phase III Trial to Evaluate CD34+ Selected Versus Unselected Autologous Peripheral Blood Progenitor Cell Transplantation in Multiple Myeloma. Blood 93: 1858-1868 [Abstract] [Full Text]  
• Rousselot, P., Labaume, S., Marolleau, J.-P., Larghero, J., Noguera, M.-H., Brouet, J.-C., Fermand, J.-P. (1999). Arsenic Trioxide and Melarsoprol Induce Apoptosis in Plasma Cell Lines and in Plasma Cells from Myeloma Patients. Cancer Res. 59: 1041-1048 [Abstract] [Full Text]  
• Smith, M.L., Newland, A.C. (1999). Treatment of myeloma. QJM 92: 11-14 [Full Text]  
• Fermand, J.-P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., Macro, M., Pertuiset, E., Dreyfus, F., Mariette, X., Boccacio, C., Brouet, J.-C. (1998). High-Dose Therapy and Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma: Up-front or Rescue Treatment? Results of a Multicenter Sequential Randomized Clinical Trial. Blood 92: 3131-3136 [Abstract] [Full Text]  
• Halgren, R. G., Traynor, A. E., Pillay, S., Zell, J. L., Heller, K. F., Krett, N. L., Rosen, S. T. (1998). 8Cl-cAMP Cytotoxicity in Both Steroid Sensitive and Insensitive Multiple Myeloma Cell Lines Is Mediated by 8Cl-Adenosine. Blood 92: 2893-2898 [Abstract] [Full Text]  
• Ramdas, J., Harmon, J. M. (1998). Glucocorticoid-Induced Apoptosis and Regulation of NF-{kappa}B Activity in Human Leukemic T Cells. Endocrinology 139: 3813-3821 [Abstract] [Full Text]  
• Jennings, C. D., Foon, K. A. (1997). Recent Advances in Flow Cytometry: Application to the Diagnosis of Hematologic Malignancy. Blood 90: 2863-2892 [Full Text]  
• Ozaki, S., Kosaka, M., Wakatsuki, S., Abe, M., Koishihara, Y., Matsumoto, T. (1997). Immunotherapy of Multiple Myeloma With a Monoclonal Antibody Directed Against a Plasma Cell-Specific Antigen, HM1.24. Blood 90: 3179-3186 [Abstract] [Full Text]  
• Bataille, R., Harousseau, J.-L. (1997). Multiple Myeloma. NEJM 336: 1657-1664 [Full Text]  
• Kyle, R. A. (1996). Multiple Myeloma: An Overview in 1996. The Oncologist 1: 315-323 [Abstract] [Full Text]